Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0309657 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Arisa Kobayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Denosumab, Renal Dialysis, Fractures, Bone. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the TSUBASA PROJECT of the Gender Equality Committee of the Japanese Society for Dialysis Therapy.
Abstract (Originalsprache)
Background
Patients undergoing hemodialysis are at an elevated risk of fractures; however, substantial evidence for osteoporosis treatment in this population is lacking. We explored the efficacy of denosumab, an anti-IgG2 antibody that targets the receptor activator of nuclear factor-kappa B ligand, in reducing fracture incidence and all-cause mortality in patients undergoing hemodialysis.
Methods
This retrospective cohort study—conducted from December 2013 to December 2022—evaluated the effects of denosumab on fracture incidence and all-cause mortality. Patients who initiated denosumab treatment during the study period were defined as the denosumab group, while those without a history of denosumab administration were defined as the non-denosumab group. Kaplan–Meier curves and log-rank tests were used to assess survival and fracture/mortality risks, respectively. Cox proportional hazards models were used to analyze both fractures and all-cause mortality.
Results
Among 214 patients undergoing hemodialysis, 52 (24.3%) received denosumab. The median age was 73.0 ± 11.5 years, with 92 (43.0%) females, and the median dialysis duration was 59 months (interquartile range, 6–126). During the study, thirty-seven non-denosumab-treated patients had fractures compared to eight in the denosumab group. No significant differences were observed in the unadjusted model (HR, 0.53; 95% confidence interval (CI), 0.24–1.14). Adjusting for competing mortality and clinical factors, the HR remained at 0.64 (95% CI, 0.27–1.51). Regarding all-cause mortality, we found a statistically significant difference in the unadjusted model (HR, 0.61 [95% CI, 0.38–0.98]). A significant reduction in mortality was observed in the adjusted model (HR, 0.46 [95% CI, 0.26–0.80]). Notably, the denosumab group showed a significant decrease in mortality, particularly in cardiovascular disease-related cases (HR, 0.33 [95% CI, 0.14–0.78]).
Conclusions
Denosumab may reduce all-cause mortality in patients undergoing hemodialysis, particularly in those with cardiovascular complications. This finding offers a promising direction for osteoporosis treatment in patients undergoing hemodialysis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Nephrology and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
- Human Health Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Division of Nephrology, Keijin Hospital, Tokyo, Japan.
ORCID-Profile: Ichiro Ohkido, Takashi Yokoo
Förderung
- the TSUBASA PROJECT of the Gender Equality Committee of the Japanese Society for Dialysis Therapy
Zitieren
APA
Kobayashi, A., Yaginuma, T., Kato, K., Nakashima, A., Ohkido, I., & Yokoo, T. (2024). Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0309657
Vancouver
Kobayashi A, Yaginuma T, Kato K, Nakashima A, Ohkido I, Yokoo T. Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0309657
BibTeX
@article{Kobayashi2024,
author = {Kobayashi, Arisa and Yaginuma, Tatsuhiro and Kato, Kazuhiko and Nakashima, Akio and Ohkido, Ichiro and Yokoo, Takashi},
title = {Effect of denosumab on the incidence of fractures and mortality in patients undergoing hemodialysis: A retrospective cohort study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0309657}
}
EUVIMED